Physician profile
Sheetal V Patel
NPI 1316258122
$6,010.74
in general payments reported to CMS, 2019-2025
27 companies · $786 in 2025
The $786 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,714 · 2020: $218 · 2021: $141 · 2022: $139 · 2023: $364 · 2024: $648 · 2025: $786.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,368 · Consulting Fee: $340 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,367.76 |
| Consulting Fee | $340.00 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardinal Health 108 LLC | $2,639.74 | 2019 | |
| Abbvie INC. | $548.93 | 2019-2025 | |
| Glaxosmithkline, LLC. | $329.57 | 2019-2023 | Benlysta |
| Novartis Pharmaceuticals Corporation | $329.28 | 2019-2025 | |
| Pfizer INC. | $290.53 | 2019-2025 | |
| Amgen INC. | $256.11 | 2019-2025 | Tavneos, Enbrel, Otezla |
| Halozyme INC | $250.00 | 2024 | |
| Janssen Biotech, INC. | $249.64 | 2019-2025 | Tremfya |
| Abiomed | $208.31 | 2019 | |
| Genzyme Corporation | $121.73 | 2019-2024 | |
| Cardinal Health 110 LLC | $100.00 | 2021 | |
| Mallinckrodt Hospital Products INC. | $94.91 | 2023-2025 | Acthar |
| E.R. Squibb & Sons, L.L.C. | $71.67 | 2019-2024 | Orencia |
| Horizon Therapeutics Plc | $69.73 | 2019-2020 | |
| Ucb, INC. | $66.96 | 2021-2025 | Bimzelx, Cimzia |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Therapeutics, INC. | $58.20 | 2019 | |
| Novo Nordisk INC | $56.73 | 2024-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $46.79 | 2022-2023 | Saphnelo |
| Celgene Corporation | $44.10 | 2019 | |
| Organon LLC | $33.92 | 2025 | Hadlima |
| Grifols USA, LLC | $31.29 | 2025 | Gamunex-C, Xembify |
| Lilly USA, LLC | $30.46 | 2019-2024 | Taltz |
| Bioventus LLC | $28.98 | 2025 | Durolane |
| Jazz Pharmaceuticals INC. | $14.94 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.78 | 2019 | |
| Sandoz INC. | $13.16 | 2024 | Hyrimoz |
| Sanofi-Aventis U.S. LLC | $10.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheetal Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.